What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer

Genes and Development

Volumn 27, Issue 8, 2013, Pages 836-852

  Losman, Julie Aurore ^a   Kaelin, William G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

2 oxoglutarate dependent dioxygenase; Cancer metabolism; Chondrosarcoma; Glioma; Isocitrate dehydrogenase; Leukemia

Indexed keywords

2 HYDROXYGLUTARIC ACID; HISTONE DEMETHYLASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ISOCITRATE DEHYDROGENASE 3; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RISK; CARCINOGENESIS; CATALYSIS; CELL METABOLISM; CHONDROSARCOMA; COLON CANCER; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG CANCER; NEOPLASM; PARAGANGLIOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84876889621     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.217406.113     Document Type: Review

References (182)

1. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ. 2010. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 116: 2122-2126.
2. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, et al. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114: 144-147.
3. Abdel-Wahab O, Patel J, Levine RL. 2011. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am 25: 1119-1133.
4. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334-343.
5. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, et al. 2011b. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43: 1262-1265.
6. Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y. 2012. Frequent IDH1/2 mutations in intracranial chondrosarcoma: A possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol 29: 201-206.
7. Arner ES, Holmgren A. 2000. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109.
8. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
9. Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, van der Sluijs HA, Pruijs HE, TeKoppele JM. 1999. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: Indications for a bonespecific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci 96: 1054-1058.
10. Barnes LD, Kuehn GD, Atkinson DE. 1971. Yeast diphosphopyridine nucleotide specific isocitrate dehydrogenase. Purification and some properties. Biochemistry 10: 3939-3944.
11. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez- Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, et al. 2009. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177-1182.
12. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, et al. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496-2506.
13. Berulava T, Ziehe M, Klein-Hitpass L, Mladenov E, Thomale J, Ruther U, Horsthemke B. 2013. FTO levels affect RNA modification and the transcriptome. Eur J Hum Genet 21: 317-323.
14. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, et al. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
15. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, et al. 2010. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494.
16. Block K, Gorin Y. 2012. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer 12: 627-637.
17. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, et al. 2012. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17: 72-79.
18. Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EE, et al. 2011. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69: 455-463.
19. Byeon SJ, Myung JK, Kim SH, Kim SK, Phi JH, Park SH. 2012. Distinct genetic alterations in pediatric glioblastomas. Childs Nerv Syst 28: 1025-1032.
20. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, et al. 2012. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119: 1901-1903.
21. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, et al. 2010. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254.
22. Chang C, Xu K, Shu H. 2011. The role of isocitrate dehydrogenase mutations in glioma brain tumors. In Molecular targets of CNS tumors (ed. M Garami), pp. 413-436. InTechOpen, Atalanta, GA.
23. Chao MP, Seita J, Weissman IL. 2008. Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol 73: 439-449.
24. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, et al. 2012. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18: 624-629.
25. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, et al. 2011. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118: 3803-3810.
26. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12: 463-469.
27. Cloos PA, Christensen J, Agger K, Helin K. 2008. Erasing the methyl mark: Histone demethylases at the center of cellular differentiation and disease. Genes Dev 22: 1115-1140.
28. Comte B, Vincent G, Bouchard B, Benderdour M, Des Rosiers C. 2002. Reverse flux through cardiac NADP+-isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol Heart Circ Physiol 283: H1505-H1514.
29. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, Dastugue N, Mugneret F, Lafage M, Gachard N, et al. 2010. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 24: 201-203.
30. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
31. Dalziel K. 1980. Isocitrate dehydrogenase and related oxidative decarboxylases. FEBS Lett 117: K45-K55.
32. Dang CV. 2012. Links between metabolism and cancer. Genes Dev 26: 877-890.
33. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
34. Dang L, Jin S, Su SM. 2010. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16: 387-397.
35. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
36. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, et al. 2009. Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301.
37. di Giacomo V, Rapino M, Miscia S, Di Giulio C, Cataldi A. 2009. Dual role of HIF-1a in delivering a survival or death signal in hypoxia exposed human K562 erythroleukemia cells. Cell Biol Int 33: 49-56.
38. Engqvist M, Drincovich MF, Flugge UI, Maurino VG. 2009. Two D-2-hydroxy-acid dehydrogenases in Arabidopsis thaliana with catalytic capacities to participate in the last reactions of the methylglyoxal and b-oxidation pathways. J Biol Chem 284: 25026-25037.
39. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
40. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW. 2012. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 25: 375-383.
41. Forristal CE, Winkler IG, Nowlan B, Barbier V, Walkinshaw G, Levesque JP. 2013. Pharmacologic stabilization of HIF-1a increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood 121: 759-769.
42. Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M. 2007. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 450: 309-313.
43. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, de Krijger RR, Gimenez-Roqueplo AP, Dinjens WN. 2010. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95: 1274-1278.
44. Gabriel JL, Zervos PR, Plaut GW. 1986. Activity of purified NAD-specific isocitrate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria. Metabolism 35: 661-667.
45. Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, et al. 2012. TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML study group. J ClinOncol 30: 1350-1357.
46. Gorres KL, Raines RT. 2010. Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 45: 106-124.
47. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207: 339-344.
48. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, et al. 2013. Clinical and pathologic impact of select chromatinmodulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 63: 848-854.
49. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et al. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
50. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, et al. 2012. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer 107: 1423-1432.
51. Hausinger RP. 2004. FeII/a-ketoglutarate-dependent hydroxylases and related enzymes. Crit Rev Biochem Mol Biol 39: 21-68.
52. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al. 2011. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
53. He M, Wang QY, Yin QQ, Tang J, Lu Y, Zhou CX, Duan CW, Hong DL, Tanaka T, Chen GQ, et al. 2013. HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: A role in myeloid leukemic cell differentiation. Cell Death Differ 20: 408-418.
54. Herz HM, Madden LD, Chen Z, Bolduc C, Buff E, Gupta R, Davuluri R, Shilatifard A, Hariharan IK, Bergmann A. 2010. The H3K27me3 demethylase dUTX is a suppressor of Notchand Rb-dependent tumors in Drosophila. Mol Cell Biol 30: 2485-2497.
55. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, et al. 2010. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566.
56. Hu Z, Gomes I, Horrigan SK, Kravarusic J, Mar B, Arbieva Z, Chyna B, Fulton N, Edassery S, Raza A, et al. 2001. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 20: 6946-6954.
57. Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, et al. 2003. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: Possible mediation of hypoxia-inducible factor-1a. Leukemia 17: 2065-2073.
58. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. 2010. Role of Tet proteins in 5mC to 5hmC conversion, EScell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
59. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. 2011. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1303.
60. Jacob B, Osato M. 2009. Stem cell exhaustion and leukemogenesis. J Cell Biochem 107: 393-399.
61. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. 2009. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113: 6403-6410.
62. Jia G, Yang CG, Yang S, Jian X, Yi C, Zhou Z, He C. 2008. Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. FEBS Lett 582: 3313-3319.
63. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, et al. 2013. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73: 496-501.
64. Jo SH, Lee SH, Chun HS, Lee SM, Koh HJ, Lee SE, Chun JS, Park JW, Huh TL. 2002. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase. Biochem Biophys Res Commun 292: 542-549.
65. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. 2005. Redox regulation of NF-kB activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7: 395-403.
66. Kaelin WG Jr. 2011. Cancer and altered metabolism: Potential importance of hypoxia-inducible factor and 2-oxoglutaratedependent dioxygenases. Cold Spring Harb Symp Quant Biol 76: 335-345.
67. Kaelin WG Jr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402.
68. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH. 2009. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355.
69. Kim SY, Lee SM, Tak JK, Choi KS, Kwon TK, Park JW. 2007. Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase. Mol Cell Biochem 302: 27-34.
70. Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M, Ohgaki H. 2011. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64: 850-852.
71. King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682.
72. Kirsch M, De Groot H. 2001. NAD(P)H, a directly operating antioxidant? FASEB J 15: 1569-1574.
73. Klose RJ, Kallin EM, Zhang Y. 2006. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7: 715-727.
74. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al. 2010. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839-843.
75. Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, Park JW, Park DC, Song BJ, Veech RL, et al. 2004. Cytosolic NADP+- dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem 279: 39968-39974.
76. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, et al. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483: 484-488.
77. Kolker S, Pawlak V, Ahlemeyer B, Okun JG, Horster F, Mayatepek E, Krieglstein J, Hoffmann GF, Kohr G. 2002. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci 16: 21-28.
78. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, et al. 2010. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/ myeloproliferative neoplasms. Leukemia 24: 1094-1096.
79. Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J, Adam E, Kozma A, Orban TI, Lovas N, et al. 2012. Type and location of isocitrate dehydrogenasemutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leuk Lymphoma doi: 10.3109/10428194.2012.736981.
80. Koyama-Nasu R, David G, Tanese N. 2007. The F-box protein Fbl10 is a novel transcriptional repressor of c-Jun. Nat Cell Biol 9: 1074-1080.
81. Kranendijk M, Struys EA, Gibson KM, Wickenhagen WV, Abdenur JE, Buechner J, Christensen E, de Kremer RD, Errami A, Gissen P, et al. 2010. Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum Mutat 31: 279-283.
82. Kranendijk M, Salomons GS, Gibson KM, Van Schaftingen E, Jakobs C, Struys EA. 2011. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies. Biochim Biophys Acta 1812: 1380-1384.
83. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. 2012. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 35: 571-587.
84. Latini A, Scussiato K, Rosa RB, Llesuy S, Bello-Klein A, Dutra- Filho CS, Wajner M. 2003. D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur J Neurosci 17: 2017-2022.
85. Latini A, da Silva CG, Ferreira GC, Schuck PF, Scussiato K, Sarkis JJ, Dutra Filho CS, Wyse AT, Wannmacher CM, Wajner M. 2005. Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. Mol Genet Metab 86: 188-199.
86. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. 2002. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32: 1185-1196.
87. Lee SH, Jo SH, Lee SM, Koh HJ, Song H, Park JW, Lee WH, Huh TL. 2004. Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by g-rays. Int J Radiat Biol 80: 635-642.
88. Lee DH, Jin SG, Cai S, Chen Y, Pfeifer GP, O'Connor TR. 2005. Repair of methylation damage in DNA and RNA by mammalian AlkB homologues. J Biol Chem 280: 39448-39459.
89. Lee JH, Kim SY, Kil IS, Park JW. 2007. Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+- dependent isocitrate dehydrogenase. J Biol Chem282: 13385-13394.
90. Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I, Pollina EA, Rabitz HA, Rabinowitz JD, Coller HA. 2010. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 8: e1000514.
91. Leonardi R, Subramanian C, Jackowski S, Rock CO. 2012. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 287: 14615-14620.
92. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, et al. 2013. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-oncol 15: 57-68.
93. Liu W, Guo M, Xu YB, Li D, Zhou ZN, Wu YL, Chen Z, Kogan SC, Chen GQ. 2006. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood 107: 698-707.
94. Locasale JW, Cantley LC. 2011. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 14: 443-451.
95. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. 2003. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17: 637-641.
96. Losman JA, Looper R, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley G, Root D, Ebert BL, Kaelin WG Jr. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339: 1621-1625.
97. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
98. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441-464.
99. Lyssiotis CA, Cantley LC. 2012. SIRT6 puts cancer metabolism in the driver's seat. Cell 151: 1155-1156.
100. Mahon PC, Hirota K, Semenza GL. 2001. FIH-1: A novel protein that interacts with HIF-1a and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686.
101. Mailloux RJ, Beriault R, Lemire J, Singh R, Chenier DR, Hamel RD, Appanna VD. 2007. The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE 2: e690.
102. Marciniak-Czochra A, Stiehl T, Ho AD, Jager W, Wagner W. 2009. Modeling of asymmetric cell division in hematopoietic stem cells-regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev 18: 377-385.
103. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, et al. 2010. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 28: 2348-2355.
104. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
105. Matsumoto A, Nakayama KI. 2013. Role of key regulators of the cell cycle in maintenance of hematopoietic stem cells. Biochim Biophys Acta 1830: 2335-2344.
106. Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, Bovee JV. 2012. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 51: 899-909.
107. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. 2012. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151: 1417-1430.
108. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, et al. 2012. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481: 380-384.
109. Miyata T, Takizawa S, van Ypersele de Strihou C. 2011. Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: Novel therapeutic targets. Am J Physiol Cell Physiol 300: C226-C231.
110. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ. 2009. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 27: 4002-4006.
111. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye- Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, et al. 2011. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11-24.
112. Newsholme P, Krause M. 2012. Nutritional regulation of insulin secretion: Implications for diabetes. Clin Biochem Rev 33: 35-47.
113. Newsholme P, Gaudel C, McClenaghan NH. 2010. Nutrient regulation of insulin secretion and b-cell functional integrity. Adv Exp Med Biol 654: 91-114.
114. Oermann EK, Wu J, Guan KL, Xiong Y. 2012. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 23: 370-380.
115. Orford KW, Scadden DT. 2008. Deconstructing stem cell selfrenewal: Genetic insights into cell-cycle regulation. Nat Rev Genet 9: 115-128.
116. Pansuriya TC, Kroon HM, Bovee JV. 2010. Enchondromatosis: Insights on the different subtypes. Int J Clin Exp Pathol. 3: 557-569.
117. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, et al. 2011. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43: 1256-1261.
118. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. 2010. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24: 1146-1151.
119. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
120. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, et al. 2010. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28: 3636-3643.
121. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. 2012. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic study of 277 patients. Leukemia 26: 101-105.
122. Perez C, Martinez-Calle N, Martin-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, et al. 2012. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS ONE 7: e31605.
123. Pollard PJ, Wortham NC, Tomlinson IP. 2003. The TCA cycle and tumorigenesis: The examples of fumarate hydratase and succinate dehydrogenase. Ann Med 35: 632-639.
124. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, et al. 2012. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 3: 850-855.
125. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. 2011. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37: 428-430.
126. Raiber EA, Beraldi D, Ficz G, Burgess HE, Branco MR, Murat P, Oxley D, Booth MJ, Reik W, Balasubramanian S. 2012. Genome-wide distribution of 5-formylcytosine in embryonic stem cells is associated with transcription and depends on thymine DNA glycosylase. Genome Biol 13: R69.
127. Raimundo N, Baysal BE, Shadel GS. 2011. Revisiting the TCA cycle: Signaling to tumor formation. Trends Mol Med 17: 641-649.
128. Rakheja D, Konoplev S, Medeiros LJ, Chen W. 2012. IDH mutations in acute myeloid leukemia. Hum Pathol 43: 1541-1551.
129. Reitman ZJ, Yan H. 2010. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941.
130. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. 2008. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134: 145-155.
131. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science doi: 10.1126/ science.1236062.
132. Rzem R, Vincent MF, Van Schaftingen E, Veiga-da-Cunha M. 2007. L-2-hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis 30: 681-689.
133. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, Cairns RA, McCracken S, Wakeham A, Haight J, et al. 2012a. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26: 2038-2049.
134. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, Harris IS, Holmes R, Wakeham A, Haight J, et al. 2012b. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488: 656-659.
135. Sazanov LA, Jackson JB. 1994. Proton-translocating transhydrogenase and NAD- and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria. FEBS Lett 344: 109-116.
136. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, et al. 2012. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151: 1185-1199.
137. Seita J, Weissman IL. 2010. Hematopoietic stem cell: Selfrenewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2: 640-653.
138. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, et al. 2010. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70: 8981-8987.
139. Semenza GL. 2012. Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408.
140. Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez JA, Maulik N, Maulik G. 2012. HIF-prolyl hydroxylases and cardiovascular diseases. Toxicol Mech Methods 22: 347-358.
141. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, et al. 2011. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22: 2616-2624.
142. Shilatifard A. 2006. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem 75: 243-269.
143. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
144. Sola S, Xavier JM, Santos DM, Aranha MM, Morgado AL, Jepsen K, Rodrigues CM. 2011. p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS ONE 6: e18421.
145. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. 2012. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103: 269-273.
146. Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PW, Bauer C, Munzel M, Wagner M, Muller M, Khan F, et al. 2013. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152: 1146-1159.
147. Steenweg ME, Jakobs C, Errami A, van Dooren SJ, Adeva Bartolome MT, Aerssens P, Augoustides-Savvapoulou P, Baric I, Baumann M, Bonafe L, et al. 2010. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: A genotype-phenotype study. Hum Mutat 31: 380-390.
148. Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen WJ, Verhoeven NM, Jakobs C. 2005a. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2- hydroxyglutaric aciduria. Am J Hum Genet 76: 358-360.
149. Struys EA, Verhoeven NM, Ten Brink HJ, Wickenhagen WV, Gibson KM, Jakobs C. 2005b. Kinetic characterization of human hydroxyacid-oxoacid transhydrogenase: Relevance to D-2-hydroxyglutaric and g-hydroxybutyric acidurias. J Inherit Metab Dis 28: 921-930.
150. Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, Irier H, Upadhyay AK, Gearing M, Levey AI, et al. 2011. 5-hmCmediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14: 1607-1616.
151. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
152. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, et al. 2009. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23: 905-911.
153. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, et al. 2010. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24: 1302-1309.
154. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, McClure RF, Pardanani A. 2012. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26: 475-480.
155. Teodoro JG, Parker AE, Zhu X, Green MR. 2006. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313: 968-971.
156. Terashima M, Ishimura A, Yoshida M, Suzuki Y, Sugano S, Suzuki T. 2010. The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase. Biochem Biophys Res Commun 399: 238-244.
157. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, et al. 2010. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95: 1668-1674.
158. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
159. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
160. Varier RA, Timmers HT. 2011. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 1815: 75-89.
161. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, Kofler J, Lu C, Tihan T, Sullivan LM, et al. 2013. Histone 3 Lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J Neuropathol Exp Neurol 72: 298-306.
162. Wallace DC. 2012. Mitochondria and cancer. Nat Rev Cancer 12: 685-698.
163. Wang JK, Tsai MC, Poulin G, Adler AS, Chen S, Liu H, Shi Y, Chang HY. 2010. The histone demethylase UTX enables RBdependent cell fate control. Genes Dev 24: 327-332.
164. Wang F, Travins J, de la Barre B, Lacronique-Penard V, Schalm S, Hansen E, Straley KS, Kernytsky A, Liu W, Gliser C, et al. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science doi: 10.1126/science. 1234769.
165. Warburg O. 1956. On the origin of cancer cells. Science 123: 309-314.
166. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
167. Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB. 2012. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31: 2491-2498.
168. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. 2013. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288: 3804-3815.
169. Wickenhagen WV, Salomons GS, Gibson KM, Jakobs C, Struys EA. 2009. Measurement of D:-2-hydroxyglutarate dehydrogenase activity in cell homogenates derived from D:-2- hydroxyglutaric aciduria patients. J Inherit Metab Dis 32: 264-268.
170. Willers IM, Cuezva JM. 2011. Post-transcriptional regulation of the mitochondrial H+-ATP synthase: A key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 1807: 543-551.
171. Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D. 2011. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1a upregulation in adult glioma. Acta Neuropathol 121: 279-281.
172. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. 2011. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci 108: 19611-19616.
173. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, Ding J. 2004. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 279: 33946-33957.
174. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
175. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, et al. 2012. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7: 201-207.
176. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
177. Yen KE, Bittinger MA, Su SM, Fantin VR. 2010. Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 29: 6409-6417.
178. Zhang J, Chen GQ. 2009. Hypoxia-HIF-1a-C/EBPa/Runx1 signaling in leukemic cell differentiation. Pathophysiology 16: 297-303.
179. Zhang J, Song LP, Huang Y, Zhao Q, Zhao KW, Chen GQ. 2008. Accumulation of hypoxia-inducible factor-1 a protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica 93: 1480-1487.
180. Zhang Y, Wei H, Tang K, Lin D, Zhang C, Mi Y, Wang L, Wang C, Wang M, Wang J. 2012. Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers. 16: 991-995.
181. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF- 1a. Science 324: 261-265.
182. Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF. 2012. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: A meta-analysis. Leuk Lymphoma 53: 2423-2429.